Business Context and Reporting Period
The provided filing is a Form 10-Q for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It covers the unaudited quarter and nine months ended September 30, 2012, and was filed November 14, 2012. Zeta describes itself as a development-stage, blank-check and shell company formed to identify and complete a business combination. It had no operating business, revenue, or identified acquisition target.
Key Financial Metrics
| Metric | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 | Comparison |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue since inception |
| Net loss | $(6,013) | $(17,653) | Prior-year periods: $(6,267) and $(18,156) |
| Operating loss | $(4,728) | $(13,965) | Prior-year periods: $(5,360) and $(15,464) |
| Interest expense | $1,285 | $3,688 | Prior-year periods: $907 and $2,692 |
| Net loss per share | $(0.00) | $(0.00) | Basic and diluted |
| Cash flow from operations | Not separately provided | $(23,634) | Prior year: $(20,743) |
| Cash flow from financing | Not separately provided | $25,000 | Prior year: $0 |
| Cash and cash equivalents | $5,586 at September 30, 2012 | $4,220 at December 31, 2011 |
At September 30, 2012, total assets were $11,461, including $5,586 of cash and $5,875 of prepaid expenses. Current liabilities totaled $97,145, including $85,000 of notes payable to stockholders, $10,012 of accrued interest, $633 of accounts payable, and $1,500 of accrued expenses. Stockholders’ deficit was $(85,684). No meaningful revenue or operating margin was reported because the company had no operating activities.
Material Changes Versus Prior Comparable Period
- Third-quarter net loss decreased modestly to $6,013 from $6,267; nine-month net loss decreased to $17,653 from $18,156.
- Nine-month operating cash use increased to $23,634 from $20,743.
- The company received $25,000 of additional stockholder loans during the first nine months of 2012, increasing notes payable to stockholders from $60,000 at December 31, 2011 to $85,000 at September 30, 2012.
- Accrued interest increased from $6,324 to $10,012.
- Cash increased by $1,366 during the first nine months, ending at $5,586, primarily because financing proceeds exceeded operating cash use.
Guidance, Outlook, Risks and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and investigating, analyzing, and potentially consummating an acquisition. No specific transaction, target, timing, or financial guidance was provided.
- Management stated that the company’s ability to continue as a going concern depends on obtaining additional financing, generating future profitable operations, and completing a suitable business combination.
- Funding has depended on stockholder loans and other capital sources. The 2012 stockholder loans are unsecured, bear 6% interest, and are due on demand.
- There is no assurance that additional funding will be available or that an acquisition will be completed.
- A future combination could involve a financially unstable or early-stage business, substantial risk, limited diversification, and dilution of existing stockholders.
- The company has generated no revenue since inception and has no operating cash flow source.
- Approximately $46,100 of gross deferred tax assets were fully offset by a valuation allowance because realization was uncertain.
- The company reported no material legal proceedings or material off-balance-sheet arrangements. Management concluded that disclosure controls were effective as of September 30, 2012.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Zeta Acquisition Corp. III, while the request identifies Kura Oncology, Inc.
- Verify the $85,000 of demand notes payable to stockholders and the $10,012 of accrued unpaid interest.
- Assess the going-concern disclosure in light of only $5,586 of cash versus $97,145 of current liabilities.
- Confirm that no business combination target had been identified or contacted as of the filing.
- Review subsequent filings for financing, a reverse merger, a change in corporate identity, or other material developments.